- Home
- DAVA vs GALT Comparison
DAVA vs GALT Comparison
Compare DAVA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | GALT |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.4M | 199.2M |
| IPO Year | 2015 | 2008 |
Fundamental Metrics
Financial Performance| Metric | DAVA | GALT |
|---|---|---|
| Price | $4.42 | $2.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | 229.0K | ★ 307.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.11 | $1.22 |
| 52 Week High | $20.80 | $7.13 |
Technical Indicators
Market Signals| Indicator | DAVA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 41.99 |
| Support Level | $4.30 | $2.13 |
| Resistance Level | $5.66 | $3.32 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 61.26 | 29.76 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.